NASDAQ:MNKD - MannKind Stock Price, Price Target & More

$1.70 -0.09 (-5.03 %)
(As of 04/22/2018 06:48 AM ET)
Previous Close$1.70
Today's Range$1.67 - $1.7999
52-Week Range$0.67 - $6.96
Volume3.67 million shs
Average Volume2.60 million shs
Market Capitalization$226.19 million
P/E RatioN/A
Dividend YieldN/A
Beta2.91

About MannKind (NASDAQ:MNKD)

MannKind logoMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000

Debt

Debt-to-Equity Ratio-0.48%
Current Ratio0.65%
Quick Ratio0.62%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.74 million
Price / Sales19.27
Cash FlowN/A
Price / CashN/A
Book Value($1.81) per share
Price / Book-0.94

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-117,330,000.00
Net Margins-999.00%
Return on EquityN/A
Return on Assets-159.22%

Miscellaneous

Employees250
Outstanding Shares133,050,000

How to Become a New Pot Stock Millionaire

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.01. The biopharmaceutical company had revenue of $4.53 million for the quarter, compared to analysts' expectations of $3.22 million. View MannKind's Earnings History.

When is MannKind's next earnings date?

MannKind is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for MannKind.

What price target have analysts set for MNKD?

4 brokerages have issued twelve-month target prices for MannKind's stock. Their forecasts range from $1.00 to $2.77. On average, they anticipate MannKind's stock price to reach $1.59 in the next year. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:
  • 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (4/6/2018)
  • 2. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)

Are investors shorting MannKind?

MannKind saw a increase in short interest in March. As of March 29th, there was short interest totalling 35,944,357 shares, an increase of 1.2% from the March 15th total of 35,523,152 shares. Based on an average daily volume of 1,481,058 shares, the days-to-cover ratio is currently 24.3 days. Currently, 34.6% of the company's shares are short sold.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:
  • Dr. Michael E. Castagna, CEO & Director (Age 41)
  • Dr. David B. Thomson, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 55)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
  • Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)

Has MannKind been receiving favorable news coverage?

Media stories about MNKD stock have been trending positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MannKind earned a news impact score of 0.44 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are MannKind's major shareholders?

MannKind's stock is owned by a number of of retail and institutional investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.57%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $1.70.

How big of a company is MannKind?

MannKind has a market capitalization of $226.19 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]


MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  335 (Vote Outperform)
Underperform Votes:  446 (Vote Underperform)
Total Votes:  781
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MannKind (NASDAQ:MNKD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for MannKind in the last 12 months. Their average twelve-month price target is $1.59, suggesting that the stock has a possible downside of 6.47%. The high price target for MNKD is $2.77 and the low price target for MNKD is $1.00. There are currently 3 sell ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.501.501.752.00
Ratings Breakdown: 3 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.59$1.59$0.9150$0.9150
Price Target Upside: 6.47% downside49.68% downside71.85% downside75.27% downside

MannKind (NASDAQ:MNKD) Consensus Price Target History

Price Target History for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2018Maxim GroupDowngradeHold -> Sell$1.00HighView Rating Details
1/25/2018S&P Equity ResearchLower Price Target$3.49 -> $2.77HighView Rating Details
11/8/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
5/22/2017JPMorgan ChaseReiterated RatingUnderweightHighView Rating Details
5/11/2017Piper JaffraySet Price TargetSell$1.00MediumView Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

MannKind (NASDAQ:MNKD) Earnings History and Estimates Chart

Earnings by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.85 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

MannKind (NASDAQ MNKD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
2/27/2018Q4 2017($0.29)($0.28)$3.22 million$4.53 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.20)($0.31)$2.56 million$2.04 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.25)($0.35)$2.75 million$2.16 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
10/29/2010Q3 2010($1.95)($2.00)ViewN/AView Earnings Details
8/2/2010Q2 2010($2.00)($1.87)ViewN/AView Earnings Details
4/30/2010Q1 2010($2.20)($1.98)ViewN/AView Earnings Details
2/1/2010Q4 2009($2.05)($2.64)ViewN/AView Earnings Details
11/2/2009Q3 2009($2.45)($2.10)ViewN/AView Earnings Details
8/3/2009Q2 2009($2.80)($2.72)ViewN/AView Earnings Details
5/4/2009Q1 2009($3.25)($2.91)ViewN/AView Earnings Details
2/17/2009Q4 2008($3.20)($4.10)ViewN/AView Earnings Details
11/5/2008Q3 2008($4.00)($3.37)ViewN/AView Earnings Details
8/11/2008Q2 2008($3.70)($3.94)ViewN/AView Earnings Details
5/5/2008Q1 2008($3.90)($3.52)ViewN/AView Earnings Details
3/4/2008Q4 2007($3.90)($3.77)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MannKind (NASDAQ:MNKD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 17.73%
Insider Trading History for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2017Stuart A TrossVPBuy39,840$2.52$100,396.8059,840View SEC Filing  
12/20/2017Michael CastagnaCEOBuy8,000$2.29$18,320.0035,532View SEC Filing  
10/13/2017Kent KresaDirectorBuy166,600$6.00$999,600.00View SEC Filing  
8/10/2017Raymond W UrbanskiCMOSell296$1.15$340.402,924View SEC Filing  
6/30/2017Rosabel Realica AlinayaSVPBuy2,000$1.23$2,460.0030,091View SEC Filing  
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60403,085View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22140,456View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00212,500View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00195,000View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00180,000View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00397,996View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.0075,000View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.0050,000View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50139,024View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56158,858View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00139,450View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17729,685View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00139,450View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.0083,752View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57171,504View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00112,756View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.1240,082View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00136,016View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MannKind (NASDAQ MNKD) News Headlines

Source:
DateHeadline
MannKind - Afrezza Scripts Dip Again - Q2 Sales Underwhelming Thus FarMannKind - Afrezza Scripts Dip Again - Q2 Sales Underwhelming Thus Far
seekingalpha.com - April 20 at 4:46 PM
MannKind - Afrezza Scripts Dip Back Below 500MannKind - Afrezza Scripts Dip Back Below 500
seekingalpha.com - April 15 at 10:09 AM
MannKind (MNKD) Cut to "Hold" at ValuEngineMannKind (MNKD) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - April 14 at 1:59 PM
MannKind (MNKD) Enters Oversold Territory April 13, 2018MannKind (MNKD) Enters Oversold Territory April 13, 2018
www.zacks.com - April 13 at 9:20 AM
MannKind (MNKD) Enters Oversold TerritoryMannKind (MNKD) Enters Oversold Territory
finance.yahoo.com - April 13 at 9:20 AM
MannKind And Its Cash SituationMannKind And Its Cash Situation
seekingalpha.com - April 11 at 4:48 PM
Form SC 13G MANNKIND CORP Filed by: SABBY MANAGEMENT, LLCForm SC 13G MANNKIND CORP Filed by: SABBY MANAGEMENT, LLC
www.streetinsider.com - April 9 at 4:44 PM
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? April 09, 2018Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? April 09, 2018
www.zacks.com - April 9 at 9:14 AM
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
finance.yahoo.com - April 9 at 9:14 AM
Why MannKind Corporation Stock Sank Last MonthWhy MannKind Corporation Stock Sank Last Month
finance.yahoo.com - April 9 at 9:14 AM
MannKind Raises $26.7 Million In Stock Offering - Not EnoughMannKind Raises $26.7 Million In Stock Offering - Not Enough
seekingalpha.com - April 8 at 5:08 PM
MannKind (MNKD) Rating Increased to Hold at Zacks Investment ResearchMannKind (MNKD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:50 PM
MannKind Modeling And Afrezza ScriptsMannKind Modeling And Afrezza Scripts
seekingalpha.com - April 7 at 9:30 AM
MannKind (MNKD) Downgraded to Sell at ValuEngineMannKind (MNKD) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 6 at 1:55 PM
MannKind (MNKD) Rating Lowered to Hold at Zacks Investment ResearchMannKind (MNKD) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:37 AM
MannKinds stock sinks after direct stock offeringMannKind's stock sinks after direct stock offering
finance.yahoo.com - April 6 at 9:23 AM
Here's Why MannKind Corporation Stock Is Tanking TodayHere's Why MannKind Corporation Stock Is Tanking Today
finance.yahoo.com - April 6 at 9:23 AM
MannKind (MNKD) Earns Buy Rating from HC WainwrightMannKind (MNKD) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - April 5 at 7:26 PM
MannKind (MNKD) Downgraded to Strong Sell at BidaskClubMannKind (MNKD) Downgraded to Strong Sell at BidaskClub
www.americanbankingnews.com - April 4 at 9:30 AM
MannKind: Playing Poker In A High Stakes Game Holding A Busted Flush HandMannKind: Playing Poker In A High Stakes Game Holding A Busted Flush Hand
seekingalpha.com - April 3 at 4:49 PM
MannKind Co. (MNKD) Receives Consensus Recommendation of "Sell" from BrokeragesMannKind Co. (MNKD) Receives Consensus Recommendation of "Sell" from Brokerages
www.americanbankingnews.com - April 3 at 1:33 AM
MannKind (MNKD) Stock Rating Reaffirmed by Maxim GroupMannKind (MNKD) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - April 2 at 11:16 AM
MannKind (MNKD) Lowered to Hold at Zacks Investment ResearchMannKind (MNKD) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 1:49 PM
MannKind (MNKD) Lifted to "Hold" at Zacks Investment ResearchMannKind (MNKD) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 6:22 PM
MannKind (MNKD) Upgraded to "Buy" by Zacks Investment ResearchMannKind (MNKD) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 29 at 9:06 AM
MannKind Co. (MNKD) Short Interest Up 6.5% in MarchMannKind Co. (MNKD) Short Interest Up 6.5% in March
www.americanbankingnews.com - March 29 at 3:10 AM
MannKind Scripts Recover As Q1 Nears CompletionMannKind Scripts Recover As Q1 Nears Completion
seekingalpha.com - March 24 at 4:42 PM
MannKinds Stone-Age Technology Is Not Rolling Off The Shelves - Seeking AlphaMannKind's Stone-Age Technology Is Not Rolling Off The Shelves - Seeking Alpha
seekingalpha.com - March 21 at 5:00 PM
MannKind Scripts Dip As Company Works On Debt Structure - Seeking AlphaMannKind Scripts Dip As Company Works On Debt Structure - Seeking Alpha
seekingalpha.com - March 19 at 4:41 PM
MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences ConferenceMannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 19 at 9:13 AM
BidaskClub Downgrades MannKind (MNKD) to SellBidaskClub Downgrades MannKind (MNKD) to Sell
www.americanbankingnews.com - March 18 at 5:38 PM
MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare ConferenceMannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 9:53 AM
MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare ConferenceMannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference
feeds.benzinga.com - March 14 at 8:39 AM
MannKind (MNKD) Says STAT Study Results Accepted for Presentation at American Diabetes Association - StreetInsider.comMannKind (MNKD) Says STAT Study Results Accepted for Presentation at American Diabetes Association - StreetInsider.com
www.streetinsider.com - March 13 at 6:38 PM
MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific SessionsMannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions
finance.yahoo.com - March 13 at 9:17 AM
MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 MillionMannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million
finance.yahoo.com - March 12 at 11:42 AM
Short Interest in MannKind Co. (MNKD) Declines By 3.6%Short Interest in MannKind Co. (MNKD) Declines By 3.6%
www.americanbankingnews.com - March 12 at 2:14 AM
MannKind Co. (MNKD) Receives Average Recommendation of "Hold" from BrokeragesMannKind Co. (MNKD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 9 at 1:27 AM
Could MannKind Corporation Be a Millionaire-Maker Stock?Could MannKind Corporation Be a Millionaire-Maker Stock?
finance.yahoo.com - March 8 at 5:48 PM
How Four Managers Outperformed In A Volatile Down MonthHow Four Managers Outperformed In A Volatile Down Month
finance.yahoo.com - March 2 at 9:00 AM
MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial HypertensionMannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension
finance.yahoo.com - March 1 at 5:10 PM
3 Bright Spots in MannKind Corporation's Q4 Update3 Bright Spots in MannKind Corporation's Q4 Update
finance.yahoo.com - February 28 at 5:20 PM
MannKind (MNKD) Stock Rating Lowered by Maxim GroupMannKind (MNKD) Stock Rating Lowered by Maxim Group
www.americanbankingnews.com - February 28 at 4:04 PM
Gene Therapy Holds Out Hope for DiabeticsGene Therapy Holds Out Hope for Diabetics
www.prnewswire.com - February 28 at 9:01 AM
MannKind reports 4Q lossMannKind reports 4Q loss
finance.yahoo.com - February 28 at 9:01 AM
MannKind (MNKD) Announces  Earnings Results, Beats Estimates By $0.01 EPSMannKind (MNKD) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - February 27 at 11:14 PM
MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial ResultsMannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - February 27 at 5:20 PM
MannKind (MNKD) Scheduled to Post Quarterly Earnings on TuesdayMannKind (MNKD) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 26 at 9:36 AM
MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018
finance.yahoo.com - February 23 at 9:03 AM
Don’t Buy MannKind Corporation Stock Under Any CircumstancesDon’t Buy MannKind Corporation Stock Under Any Circumstances
investorplace.com - February 12 at 10:14 AM

SEC Filings

MannKind (NASDAQ:MNKD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MannKind (NASDAQ MNKD) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.